Pfizer Terminates Domagrozumab trial for the treatment of Duchenne muscular dystrophy

 Pfizer Terminates Domagrozumab trial for the treatment of Duchenne muscular dystrophy

Pfizer Terminates Domagrozumab trial for the treatment of Duchenne muscular dystrophy

Shots:
  • The termination is based on two ongoing evaluation studies, P-II study (NCT02310763) and open label study(NCT02907619), which didn’t meet efficacy endpoints for showing the difference in mean change from baseline in 4 Stair Climb (in sec) with one year of treatment vs PBO
  • The P-II (N=121 boys) aged (6 to 15yrs.) administering monthly IV doses designed for two years and open-label to evaluate long-term safety and efficacy of domagrozumab
  • The studies were not terminated for safety reasons and company will review the data. Pfizer is also conducting a trial in DMD with gene therapy

Click here to read full press release/ article | Ref: Pfizer | Image:  Pfizer

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post